166 related articles for article (PubMed ID: 24575359)
1. Association of Over-Expressed Estrogen Receptor Alpha with Development of Tamoxifen Resistant Hyperplasia and Adenocarcinomas in Genetically Engineered Mice.
Miermont AM; Cabrera MC; Frech SM; Nakles RE; Diaz-Cruz ES; Shiffert MT; Furth PA
Anat Physiol; 2012 Jun; Suppl 12():. PubMed ID: 24575359
[TBL] [Abstract][Full Text] [Related]
2. Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer.
Jones LP; Li M; Halama ED; Ma Y; Lubet R; Grubbs CJ; Deng CX; Rosen EM; Furth PA
Oncogene; 2005 May; 24(22):3554-62. PubMed ID: 15750629
[TBL] [Abstract][Full Text] [Related]
3. Loss of cyclin D1 in concert with deregulated estrogen receptor alpha expression induces DNA damage response activation and interrupts mammary gland morphogenesis.
Frech MS; Torre KM; Robinson GW; Furth PA
Oncogene; 2008 May; 27(22):3186-93. PubMed ID: 18071314
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.
Alao JP; Lam EW; Ali S; Buluwela L; Bordogna W; Lockey P; Varshochi R; Stavropoulou AV; Coombes RC; Vigushin DM
Clin Cancer Res; 2004 Dec; 10(23):8094-104. PubMed ID: 15585645
[TBL] [Abstract][Full Text] [Related]
5. Annonacin induces cell cycle-dependent growth arrest and apoptosis in estrogen receptor-α-related pathways in MCF-7 cells.
Ko YM; Wu TY; Wu YC; Chang FR; Guh JY; Chuang LY
J Ethnopharmacol; 2011 Oct; 137(3):1283-90. PubMed ID: 21840388
[TBL] [Abstract][Full Text] [Related]
6. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
7. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.
Stendahl M; Kronblad A; Rydén L; Emdin S; Bengtsson NO; Landberg G
Br J Cancer; 2004 May; 90(10):1942-8. PubMed ID: 15138475
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells.
Kilker RL; Hartl MW; Rutherford TM; Planas-Silva MD
J Steroid Biochem Mol Biol; 2004 Sep; 92(1-2):63-71. PubMed ID: 15544931
[TBL] [Abstract][Full Text] [Related]
9. Role of ERalpha in the differential response of Stat5a loss in susceptibility to mammary preneoplasia and DMBA-induced carcinogenesis.
Miermont AM; Parrish AR; Furth PA
Carcinogenesis; 2010 Jun; 31(6):1124-31. PubMed ID: 20181624
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor alpha is required for mammary development and the induction of mammary hyperplasia and epigenetic alterations in the aromatase transgenic mice.
Tekmal RR; Liu YG; Nair HB; Jones J; Perla RP; Lubahn DB; Korach KS; Kirma N
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):9-15. PubMed ID: 15955696
[TBL] [Abstract][Full Text] [Related]
11. HEXIM1 regulates 17beta-estradiol/estrogen receptor-alpha-mediated expression of cyclin D1 in mammary cells via modulation of P-TEFb.
Ogba N; Chaplin LJ; Doughman YQ; Fujinaga K; Montano MM
Cancer Res; 2008 Sep; 68(17):7015-24. PubMed ID: 18757415
[TBL] [Abstract][Full Text] [Related]
12. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
13. Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer.
Díaz-Cruz ES; Sugimoto Y; Gallicano GI; Brueggemeier RW; Furth PA
Cancer Res; 2011 Aug; 71(16):5477-87. PubMed ID: 21840986
[TBL] [Abstract][Full Text] [Related]
14. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
[TBL] [Abstract][Full Text] [Related]
15. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 determines estrogen signaling in the mammary gland in vivo.
Casimiro MC; Wang C; Li Z; Di Sante G; Willmart NE; Addya S; Chen L; Liu Y; Lisanti MP; Pestell RG
Mol Endocrinol; 2013 Sep; 27(9):1415-28. PubMed ID: 23864650
[TBL] [Abstract][Full Text] [Related]
17. BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells.
Nakuci E; Mahner S; Direnzo J; ElShamy WM
Exp Cell Res; 2006 Oct; 312(16):3120-31. PubMed ID: 16860316
[TBL] [Abstract][Full Text] [Related]
18. Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells.
Kilker RL; Planas-Silva MD
Cancer Res; 2006 Dec; 66(23):11478-84. PubMed ID: 17145896
[TBL] [Abstract][Full Text] [Related]
19. Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content.
Nakles RE; Shiffert MT; Díaz-Cruz ES; Cabrera MC; Alotaiby M; Miermont AM; Riegel AT; Furth PA
Mol Endocrinol; 2011 Apr; 25(4):549-63. PubMed ID: 21292825
[TBL] [Abstract][Full Text] [Related]
20. AIB1 sequestration by androgen receptor inhibits estrogen-dependent cyclin D1 expression in breast cancer cells.
De Amicis F; Chiodo C; Morelli C; Casaburi I; Marsico S; Bruno R; Sisci D; Andò S; Lanzino M
BMC Cancer; 2019 Nov; 19(1):1038. PubMed ID: 31684907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
